JP2007538105A - Ｇｓｔ活性化抗癌化合物による治療による別の抗癌療法の増感および／または別の抗癌療法の副作用の改善 - Google Patents

Ｇｓｔ活性化抗癌化合物による治療による別の抗癌療法の増感および／または別の抗癌療法の副作用の改善 Download PDF

Info

Publication number
JP2007538105A
JP2007538105A JP2007527521A JP2007527521A JP2007538105A JP 2007538105 A JP2007538105 A JP 2007538105A JP 2007527521 A JP2007527521 A JP 2007527521A JP 2007527521 A JP2007527521 A JP 2007527521A JP 2007538105 A JP2007538105 A JP 2007538105A
Authority
JP
Japan
Prior art keywords
therapy
gst
cancer
compound
anticancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007527521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007538105A5 (enExample
Inventor
ゲイル・エル・ブラウン
ジェイムズ・ジー・ケック
マイケル・エム・ウィック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terrapin Technologies Inc
Original Assignee
Terrapin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terrapin Technologies Inc filed Critical Terrapin Technologies Inc
Publication of JP2007538105A publication Critical patent/JP2007538105A/ja
Publication of JP2007538105A5 publication Critical patent/JP2007538105A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007527521A 2004-05-20 2005-05-19 Ｇｓｔ活性化抗癌化合物による治療による別の抗癌療法の増感および／または別の抗癌療法の副作用の改善 Pending JP2007538105A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57279004P 2004-05-20 2004-05-20
PCT/US2005/017960 WO2005112973A1 (en) 2004-05-20 2005-05-19 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound

Publications (2)

Publication Number Publication Date
JP2007538105A true JP2007538105A (ja) 2007-12-27
JP2007538105A5 JP2007538105A5 (enExample) 2008-07-03

Family

ID=34970551

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007527521A Pending JP2007538105A (ja) 2004-05-20 2005-05-19 Ｇｓｔ活性化抗癌化合物による治療による別の抗癌療法の増感および／または別の抗癌療法の副作用の改善

Country Status (12)

Country Link
US (2) US20050261202A1 (enExample)
EP (1) EP1755632A1 (enExample)
JP (1) JP2007538105A (enExample)
KR (1) KR101174685B1 (enExample)
CN (1) CN1953762B (enExample)
AR (1) AR048971A1 (enExample)
AU (1) AU2005245004B2 (enExample)
BR (1) BRPI0511296A (enExample)
CA (1) CA2566850A1 (enExample)
MX (1) MXPA06013375A (enExample)
TW (1) TW200538149A (enExample)
WO (1) WO2005112973A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528890A (ja) * 2009-06-05 2012-11-15 ティーエーユー・セラピューティクス・エルエルシー 癌または前癌状態を治療するための組み合わせ方法

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
ES2293834B1 (es) 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
EP2091914A4 (en) * 2006-11-08 2010-12-29 Chongxi Yu TRANSDERMAL ADMINISTRATION SYSTEMS FOR PEPTIDES AND RELATED CONNECTIONS
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
BRPI0809937A2 (pt) * 2007-04-14 2014-09-23 Southern Res Inst Métodos de potencialização de tratamento de radioterapia, de intensificação da radiossensibilidade e de diminuição da proliferação de população de células e de tratamento do crescimento de tumor
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
CA2704395A1 (en) * 2007-11-02 2009-05-14 Ziopharm Oncology, Inc. Combination therapy with organic arsenicals
ES2332557B1 (es) 2007-12-04 2011-02-02 Universidad Autonoma De Madrid Huella genomica para el pronostico de la evolucion de adenocarcinoma colorectal.
ES2332167B1 (es) 2007-12-04 2010-10-25 Universidad Autonoma De Madrid Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal.
CN102006875A (zh) * 2008-02-08 2011-04-06 帕纳德制药公司 吡铂和贝伐单抗治疗结直肠癌的用途
ES2476602T3 (es) * 2008-03-14 2014-07-15 Bionumerik Pharmaceuticals, Inc. Composiciones y métodos quimioprotectores
ES2338843B1 (es) 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
EP2169078A1 (en) 2008-09-26 2010-03-31 Fundacion Gaiker Methods and kits for the diagnosis and the staging of colorectal cancer
BRPI1011439B8 (pt) 2009-05-08 2021-05-25 Yu Chongxi composição de alta penetração, composição farmacêutica, sistemas de aplicação terapêutico transdérmico e uso da referida composição
MX360640B (es) 2010-03-01 2018-11-09 Tau Therapeutics Llc Star Diagnosis e imagenologia de cancer.
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
US20120288554A1 (en) * 2011-05-12 2012-11-15 Telik, Inc. Canfosfamide monotherapy for treating multiple myeloma
WO2013092960A1 (en) 2011-12-22 2013-06-27 Fundacion Gaiker Methods and kits for the diagnosis of colorectal cancer
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN106573062B (zh) 2014-06-17 2020-08-25 日东电工株式会社 细胞凋亡诱导剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508980A (ja) * 2002-11-15 2006-03-16 テリック，インコーポレイテッド Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556942A (en) * 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5767147A (en) * 1995-04-21 1998-06-16 The Regents Of The University Of California Inhibition of glutathione transferase by haloenol lactones
WO1996040205A1 (en) 1995-06-07 1996-12-19 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5880097A (en) * 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508980A (ja) * 2002-11-15 2006-03-16 テリック，インコーポレイテッド Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5007014497; ＣＬＩＮＩＣＡＬ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖｏｌ．９，　Ｎｏ．１６, 20031201, ｐ．６２４１Ｓ-６２４２Ｓ *
JPN5007014498; ＥＵＲＯＰＥＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＡＮＣＥＲ Ｖｏｌ．３８, 200211, ｐ．Ｓ３５, ＰＥＲＧＡＭＯＮ　ＰＲＥＳＳ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528890A (ja) * 2009-06-05 2012-11-15 ティーエーユー・セラピューティクス・エルエルシー 癌または前癌状態を治療するための組み合わせ方法
JP2016028058A (ja) * 2009-06-05 2016-02-25 ティーエーユー・セラピューティクス・エルエルシー 癌または前癌状態を治療するための組み合わせ方法

Also Published As

Publication number Publication date
US8207121B2 (en) 2012-06-26
AU2005245004B2 (en) 2011-08-04
AR048971A1 (es) 2006-06-14
CN1953762B (zh) 2012-04-25
TW200538149A (en) 2005-12-01
KR101174685B1 (ko) 2012-08-16
WO2005112973A1 (en) 2005-12-01
US20080166428A1 (en) 2008-07-10
BRPI0511296A (pt) 2007-12-04
AU2005245004A1 (en) 2005-12-01
MXPA06013375A (es) 2007-03-01
CN1953762A (zh) 2007-04-25
EP1755632A1 (en) 2007-02-28
CA2566850A1 (en) 2005-12-01
KR20070012542A (ko) 2007-01-25
US20050261202A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
JP2007538105A (ja) Ｇｓｔ活性化抗癌化合物による治療による別の抗癌療法の増感および／または別の抗癌療法の副作用の改善
JP2010265305A (ja) Ｇｓｔ活性化された抗癌化合物と他の抗癌治療との併用癌治療
RU2571551C1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
JP4991107B2 (ja) コンブレタスタチンおよび抗癌剤からなる組成物
KR20000016749A (ko) Naaladase 억제제로서 사용가능한 특정의 포스피닐 유도체
JP2006508980A5 (enExample)
TW202028182A (zh) 用於癌症治療之免疫調節之組合
Schilder et al. New therapies for ovarian cancer
TW202011946A (zh) 以bet抑制劑及蛋白酶體抑制劑之組合療法
Natsume et al. Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs
SK10332003A3 (sk) Farmaceutický prostriedok na inhibíciu rastu nádorov a/alebo nádorových buniek

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080515

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110418

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111019

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111117

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20111209